v**********m
发帖数: 5516 | 1 http://seekingalpha.com/article/894061-delcath-systems-an-exclu
Delcath Systems: An Exclusive Interview With ROTH Capital Senior Analyst
September 28, 2012 | about: DCTH
Disclosure: I am long DCTH. (More...)
Today I have the pleasure of publishing an exclusive interview that took
place this week between me and one of the leading senior analysts for
medical technology, Mr. Matt Dolan of ROTH Capital Partners. Mr. Dolan has
followed the industry for nearly a decade and has been the senior analys... 阅读全帖 |
|
v**********m
发帖数: 5516 | 2 本人觉得AF有些扯淡，特别是那个DCTH替FDA说话的那段。AF觉得自己是豪猪吗？还吓
得后颈毛都竖起来。
在AF提供的时间点内可以做做波段。
by- Var.
--------------------------------
D. Jones asks, "Do you have an opinion on Delcath Systems(DCTH)? They are
submitting their NDA [New Drug Application] later this year and I was
wondering if it's time to buy before a potential run-up."
I'm not a Delcath fan, never been one, mainly because of the small
commercial market for the company's Chemosaturation (ChemoSat) liver-tumor
treatment system. I haven't had big concer... 阅读全帖 |
|
v**********m
发帖数: 5516 | 3 8/10/2012 5:34 AM ET
(RTTNews) - Having transitioned from a development stage company to a
commercial organization with operational activities in April of this year,
Delcath Systems Inc. (DCTH:Quote) is gearing up to play its part of
NDA resubmission in the upcoming binary event.
The company's shares have lost over 40% of their value year-to-date, and
trade near their 52-week low. With the company scheduled to resubmit the New
Drug Application for its proprietary chemosaturation system
in a coup... 阅读全帖 |
|
g****e
发帖数: 1426 | 4 Watching AMRN, it seems the train is taking off. Its value is there and
getting great attention. Big money is buying. If you don't know Vascepa
market potential value, think about Lipitor. It is a blockbuster opportunity
and multiple billion $$$ annual saleat peak. AMRN has no sale team and are
not capable to build it, buyout(@20s short term) is the only outcome. Don't
miss the opportunity,buy and hold.
I am looking for ARNA like companies(>100% upside) for investing/gambling,
highly undervalued... 阅读全帖 |
|
y*****l
发帖数: 5997 | 5 Delcath Submits CE Mark Technical File for Hepatic ChemoSAT(TM) Delivery
System
Monday 12/06/2010 6:30 AM ET - Pr Newswire
Related Companies
Symbol Last %Chg
DCTH 9.94 0.40%
As of 11:17 AM ET 12/6/10
Delcath Systems, Inc. (Nasdaq: DCTH) today announced that the Company has
submitted its CE Mark Technical File to its European Notified Body to obtain
CE Mark approval for its proprietary chemosaturation system, which the
Company intends to market in the European Union (EU) as the Delcath Hepatic
Ch... 阅读全帖 |
|
O**I
发帖数: 776 | 6 【 以下文字转载自 pennystock 俱乐部 】
发信人: OSCI (TX), 信区: pennystock
标 题: FDA Drug Approvals in 2011
发信站: BBS 未名空间站 (Sat Jan 8 17:29:50 2011, 美东)
http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
... 阅读全帖 |
|
g****e
发帖数: 1426 | 7 Due to the high risk and reward, it is hard to resist to gamble. But never
play up and down like MM!! Since MM have insider knowledges and huge funds
to manipulate share price! The only advantage we have is time. We know the
FDA decision event is coming and should buy these stocks
When the price is low ahead of time! The price will eventually go up when
the catalyst event is approaching and then we sell for gains.
Currently I have long position on AMRN, DCTH, AEGR & DVAX. Among these 4,
AMRN is ... 阅读全帖 |
|
O**I
发帖数: 776 | 8 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
O**I
发帖数: 776 | 9 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
w*******0
发帖数: 13 | 10 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
w*******0
发帖数: 13 | 11 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
